IRLAB Therapeutics AB (publ) Stock Nasdaq Stockholm
Equities
SE0012675361
Pharmaceuticals
Sales 2023 | 5.68M 525K 719K | Sales 2024 * | 23.65M 2.19M 2.99M | Capitalization | 568M 52.52M 71.89M |
---|---|---|---|---|---|
Net income 2023 | -178M -16.46M -22.53M | Net income 2024 * | -155M -14.33M -19.62M | EV / Sales 2023 | 48.9 x |
Net cash position 2023 | 111M 10.29M 14.09M | Net Debt 2024 * | 25.35M 2.34M 3.21M | EV / Sales 2024 * | 25.1 x |
P/E ratio 2023 |
-2.19
x | P/E ratio 2024 * |
-2.97
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 57.48% |
Latest transcript on IRLAB Therapeutics AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 12-12-31 |
Chief Executive Officer | 71 | 17-05-05 | |
Nicholas Waters
FOU | Founder | 62 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 15-12-31 |
Rein Piir
BRD | Director/Board Member | 66 | 15-12-31 |
Chairman | 66 | 19-03-31 |
1st Jan change | Capi. | |
---|---|---|
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |